French law: what about a reasoned reimbursement of serum vitamin D assays?
GERIATRIE ET PSYCHOLOGIE NEUROPSYCHIATRIE DE VIEILLISSEMENT(2016)
摘要
The number of serum 25-hydroxyvitamin D (25OHD) assays has increased tenfold in France in less than 10 years, sometimes for invalidated reasons. In 2013, the French National Authority for Health (Haute autorite de sante, or HAS) limited the indications for serum 25OHD measurements to rickets/osteomalacia, older adults with recurrent falls, monitoring of kidney transplant in adults, and surgical treatment of obesity in adults. Our aim here was to note that other indications for serum 25OHD measurements are supported by previous literature and by a number of national and international recommendations, in particular the following: any situation of bone fragility, any chronic renal failure <45 mL/min/1.73m(2), any situation of malabsorption, clinical signs consistent with vitamin D deficiency or vitamin D overload, and calcium phosphorus evaluation. We suggest that the measurement of serum 25OHD concentration should remain reimbursed as part of these extended indications.
更多查看译文
关键词
vitamin D,osteoporosis,osteomalacia,rickets,chronic kidney disease,clinical practice,calcium phosphorus evaluation,assay,reimbursement,France,recommendation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要